DOP2015000077A - Derivados de pirrolotriazinona como inhibidores de pi3k - Google Patents

Derivados de pirrolotriazinona como inhibidores de pi3k

Info

Publication number
DOP2015000077A
DOP2015000077A DO2015000077A DO2015000077A DOP2015000077A DO P2015000077 A DOP2015000077 A DO P2015000077A DO 2015000077 A DO2015000077 A DO 2015000077A DO 2015000077 A DO2015000077 A DO 2015000077A DO P2015000077 A DOP2015000077 A DO P2015000077A
Authority
DO
Dominican Republic
Prior art keywords
derivatives
pirrolotriazinona
pi3k inhibitors
inhibitors
pi3ks
Prior art date
Application number
DO2015000077A
Other languages
English (en)
Spanish (es)
Inventor
Montserrat Erra Sola
Marta Carrascal Riera
Joan Taltavull Moll
Juan Francisco Caturla Javaloyes
Francisco Javier Bernal Anchuela
Lluis Miquel Pages Santacana
Marta Mir Cepeda
Gaspar Casals Coll
Maria Begoña Hernandez Olasagarre
Original Assignee
Almirall Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Almirall Sa filed Critical Almirall Sa
Publication of DOP2015000077A publication Critical patent/DOP2015000077A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Otolaryngology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DO2015000077A 2012-10-16 2015-03-30 Derivados de pirrolotriazinona como inhibidores de pi3k DOP2015000077A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12382399 2012-10-16
US201261718782P 2012-10-26 2012-10-26

Publications (1)

Publication Number Publication Date
DOP2015000077A true DOP2015000077A (es) 2015-04-30

Family

ID=47049114

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2015000077A DOP2015000077A (es) 2012-10-16 2015-03-30 Derivados de pirrolotriazinona como inhibidores de pi3k

Country Status (29)

Country Link
US (1) US9388189B2 (https=)
EP (1) EP2909207A1 (https=)
JP (1) JP2015533181A (https=)
KR (1) KR20150068953A (https=)
CN (1) CN104854108A (https=)
AP (1) AP2015008328A0 (https=)
AR (1) AR093036A1 (https=)
AU (1) AU2013333938A1 (https=)
BR (1) BR112015007231A2 (https=)
CA (1) CA2883426A1 (https=)
CL (1) CL2015000956A1 (https=)
CR (1) CR20150175A (https=)
DO (1) DOP2015000077A (https=)
EA (1) EA027277B1 (https=)
GE (1) GEP201706623B (https=)
GT (1) GT201500094A (https=)
HK (1) HK1211027A1 (https=)
IL (1) IL237475A0 (https=)
MD (1) MD20150048A2 (https=)
MX (1) MX2015004327A (https=)
NI (1) NI201500054A (https=)
PE (1) PE20150637A1 (https=)
PH (1) PH12015500813A1 (https=)
SG (1) SG11201502032VA (https=)
TN (1) TN2015000112A1 (https=)
TW (1) TW201429975A (https=)
UY (1) UY35086A (https=)
WO (1) WO2014060432A1 (https=)
ZA (1) ZA201501220B (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014015523A1 (en) * 2012-07-27 2014-01-30 Hutchison Medipharma Limited Novel heteroaryl and heterocycle compounds, compositions and methods
EP2997030B1 (en) * 2013-05-14 2017-08-09 Nerviano Medical Sciences S.R.L. Pyrrolo[2,3-d]pyrimidine derivatives, process for their preparation and their use as kinase inhibitors
KR20160060100A (ko) 2013-09-22 2016-05-27 칼리토르 사이언시즈, 엘엘씨 치환된 아미노피리미딘 화합물 및 이용 방법
HK1232227A1 (zh) 2014-07-04 2018-01-05 Lupin Limited 作为pi3k抑制剂的喹嗪酮衍生物
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2016202800A1 (en) 2015-06-16 2016-12-22 Almirall, S.A. Pyrrolotriazinone derivatives as pi3k inhibitors
CN106467545B (zh) * 2015-08-20 2018-10-16 北大方正集团有限公司 一种噻吩并嘧啶化合物
WO2017076990A1 (en) 2015-11-05 2017-05-11 Almirall, S.A. Addition salts of n-[4-(4-{[(1s)-1-(5-methyl-4-oxo-3-phenyl-3,4-dihydropyrrolo[2,1-f][1,2,4]triazin-2-yl)ethyl]amino}-7h-pyrrolo[2,3-d]pyrimidin-5-yl)-1h-indol-6-yl]sulfamide
WO2017079746A2 (en) 2015-11-07 2017-05-11 Multivir Inc. Methods and compositions comprising tumor suppressor gene therapy and immune checkpoint blockade for the treatment of cancer
SMT202200190T1 (it) 2015-11-16 2022-07-21 Topadur Pharma Ag Derivati del 2-fenil-3,4-diidropirrolo[2,1-f] [1,2,4]triazinone come inibitori della fosfodesterasi e loro usi
US9630968B1 (en) 2015-12-23 2017-04-25 Arqule, Inc. Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof
WO2017214269A1 (en) 2016-06-08 2017-12-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
JP6867417B2 (ja) * 2016-06-21 2021-04-28 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ キナーゼ阻害剤としてのｎ−（置換フェニル）−スルホンアミド誘導体
TW201811795A (zh) 2016-08-24 2018-04-01 美商亞闊股份有限公司 胺基－吡咯并嘧啶酮化合物及其用途
KR20190112263A (ko) 2016-12-12 2019-10-04 멀티비르 인코포레이티드 암 및 감염성 질환의 치료 및 예방을 위한 바이러스 유전자 치료요법 및 면역 체크포인트 억제제를 포함하는 방법 및 조성물
KR102737185B1 (ko) 2018-01-20 2024-12-05 선샤인 레이크 파르마 컴퍼니 리미티드 치환된 아미노피리미딘 화합물 및 이의 사용 방법
WO2020036635A2 (en) 2018-03-19 2020-02-20 Multivir Inc. Methods and compositions comprising tumor suppressor gene therapy and cd122/cd132 agonists for the treatment of cancer
WO2021113644A1 (en) 2019-12-05 2021-06-10 Multivir Inc. Combinations comprising a cd8+ t cell enhancer, an immune checkpoint inhibitor and radiotherapy for targeted and abscopal effects for the treatment of cancer
KR102885432B1 (ko) 2020-07-03 2025-11-14 난징 이뮤노파지 바이오테크 코., 엘티디. CCR8 억제제로 Tregs를 표적화하는 방법 및 조성물

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GEP20084317B (en) * 2000-04-25 2008-02-25 Icos Corp Inhibitors of human phosphatidyl-inositol 3-kinase delta
US6667300B2 (en) 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
TW200407143A (en) * 2002-05-21 2004-05-16 Bristol Myers Squibb Co Pyrrolotriazinone compounds and their use to treat diseases
US6752411B2 (en) 2002-06-24 2004-06-22 Norco Industries, Inc. Multi-stage torsion axle
TW200400816A (en) 2002-06-26 2004-01-16 Lilly Co Eli Tricyclic steroid hormone nuclear receptor modulators
KR20060022647A (ko) 2003-04-25 2006-03-10 길리애드 사이언시즈, 인코포레이티드 키나아제 억제 포스포네이트 유사체
WO2005016348A1 (en) 2003-08-14 2005-02-24 Icos Corporation Method of inhibiting immune responses stimulated by an endogenous factor
WO2005113556A1 (en) * 2004-05-13 2005-12-01 Icos Corporation Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta
DK200400182U4 (da) 2004-06-23 2005-10-14 Alfa Laval Tank Equipment As Drivenhed især til brug i forbindelse med tankrenseudstyr
GB0417709D0 (en) 2004-08-09 2004-09-08 Glaxo Group Ltd Compounds
US8071597B2 (en) * 2005-08-26 2011-12-06 Merck Serono Sa Pyrazine compounds and uses as PI3K inhibitors
US7759350B2 (en) 2005-09-15 2010-07-20 Orchid Research Laboratories Ltd. Pyrimidine carboxamides
US7525866B2 (en) 2006-04-19 2009-04-28 Freescale Semiconductor, Inc. Memory circuit
FI20065449A0 (fi) 2006-06-29 2006-06-29 Nokia Corp Tehonkulutuksen valvontamenetelmä, tehonkulutuksen valvontalaite, tietokoneohjelmatuote, tietokoneohjelman jakeluväline ja kommunikaatioväline
TW200840581A (en) 2007-02-28 2008-10-16 Astrazeneca Ab Novel pyrimidine derivatives
UY31137A1 (es) 2007-06-14 2009-01-05 Smithkline Beecham Corp Derivados de quinazolina como inhibidores de la pi3 quinasa
ITRN20070034A1 (it) 2007-06-27 2008-12-28 Sica Spa Macchina e metodo di taglio di un tubo estruso in continuo in spezzoni di minore e predeterminata lunghezza.
TWI441601B (zh) 2007-06-28 2014-06-21 Philip Morris Products Sa 具有高白堊含量之圖案化包裝紙
US20100286145A1 (en) 2007-07-26 2010-11-11 Comentis, Inc. Isophthalamide derivatives inhibiting beta-secretase activity
WO2009147188A1 (en) 2008-06-05 2009-12-10 Glaxo Group Limited Benzpyrazol derivatives as inhibitors of pi3 kinases
US20110212053A1 (en) 2008-06-19 2011-09-01 Dapeng Qian Phosphatidylinositol 3 kinase inhibitors
BRPI1012333A2 (pt) * 2009-03-24 2016-03-29 Gilead Calistoga Llc atropisômeros de derivados de 2-purinil-3-tolil-quinazolinonas e métodos de uso
BRPI1014253A2 (pt) 2009-07-02 2016-04-12 Merz Pharma Gmbh & Co Kgaa polinucleotídeo codificado um polipeptídeo de neurotoxina, vetor, célula hospedeira, anticorpo, uso de um polinucleotídeo, método para a fabricação de um polipeptídeo de neurotoxina e método para a fabricação de um medicamento
WO2011058109A1 (en) * 2009-11-12 2011-05-19 Ucb Pharma S.A. Fused bicyclic pyrrole and imidazole derivatives as kinase inhibitors
WO2011119704A1 (en) 2010-03-23 2011-09-29 Glaxosmithkline Llc Trpv4 antagonists
CA2799579A1 (en) * 2010-05-21 2011-11-24 Intellikine, Inc. Chemical compounds, compositions and methods for kinase modulation
EP2394998A1 (en) 2010-05-31 2011-12-14 Almirall, S.A. 3-(5-Amino-6-oxo-1,6-dihydropyridazin-3-yl)-biphenyl derivatives as PDE4 inhibitors
WO2012000202A1 (zh) 2010-07-02 2012-01-05 Tsai Wen-Kai 人员派遣事务机及其应用的人员派遣方法
US8916553B2 (en) 2010-07-26 2014-12-23 Bristol-Myers Squibb Company Sulfonamide compounds useful as CYP17 inhibitors
US9006449B2 (en) 2010-07-29 2015-04-14 Oryzon Genomics, S.A. Cyclopropylamine derivatives useful as LSD1 inhibitors
JP2014515757A (ja) 2011-04-21 2014-07-03 ボード オブ スーパーバイザーズ オブ ルイジアナ ステイト ユニバーシティ アンド アグリカルチュラル アンド メカニカル カレッジ 真菌感染症のペプチド及び結合型ワクチン
EP2518070A1 (en) 2011-04-29 2012-10-31 Almirall, S.A. Pyrrolotriazinone derivatives as PI3K inhibitors
CN102229416B (zh) 2011-06-29 2013-06-05 三一汽车起重机械有限公司 一种起重机闭式回转液压系统及起重机
PT2755965T (pt) 2011-09-12 2017-11-02 Merck Patent Gmbh Novas imidazol aminas como moduladores da atividade quinase
WO2014015523A1 (en) 2012-07-27 2014-01-30 Hutchison Medipharma Limited Novel heteroaryl and heterocycle compounds, compositions and methods

Also Published As

Publication number Publication date
UY35086A (es) 2014-05-30
JP2015533181A (ja) 2015-11-19
EA027277B1 (ru) 2017-07-31
BR112015007231A2 (pt) 2017-07-04
ZA201501220B (en) 2017-04-26
WO2014060432A1 (en) 2014-04-24
MD20150048A2 (ro) 2015-10-31
TW201429975A (zh) 2014-08-01
PH12015500813B1 (en) 2015-06-08
MX2015004327A (es) 2015-06-10
GEP201706623B (en) 2017-02-10
CL2015000956A1 (es) 2015-06-19
IL237475A0 (en) 2015-04-30
GT201500094A (es) 2017-08-01
KR20150068953A (ko) 2015-06-22
AU2013333938A1 (en) 2015-04-09
NI201500054A (es) 2016-02-01
CN104854108A (zh) 2015-08-19
EA201500426A1 (ru) 2015-10-30
CA2883426A1 (en) 2014-04-24
US9388189B2 (en) 2016-07-12
EP2909207A1 (en) 2015-08-26
AP2015008328A0 (en) 2015-03-31
HK1211027A1 (en) 2016-05-13
PE20150637A1 (es) 2015-05-08
SG11201502032VA (en) 2015-05-28
US20150291595A1 (en) 2015-10-15
PH12015500813A1 (en) 2015-06-08
TN2015000112A1 (en) 2016-06-29
AR093036A1 (es) 2015-05-13
CR20150175A (es) 2015-05-11

Similar Documents

Publication Publication Date Title
CR20130543A (es) Derivados de pirrolotriazinona como inhibidores de pi3k
CR20150175A (es) Derivados de pirrolotriazinona como inhibidores de pi3k
ECSP12012042A (es) Derivados de pirazol como inhibidores de jak
MX2012014017A (es) Derivados de heteroaril imidazolona como inhibidores de jak.
CR20140031A (es) Derivados de piridin-2(1h)-ona como inhibidores de jak
UY35332A (es) Derivados de pirrolotriazina como inhibidores de pi3k
GT201300137A (es) Derivados de imidazo [1,2-b] piridazina e imidazo [4,5-b] piridina como inhibidores de jak
CO6541643A2 (es) Derivados de imidazopirina como inhibidores de jak
UY32239A (es) Nuevos derivados de (3-oxo)piridazin-4-ilurea
DOP2014000204A (es) Compuestos de heterociclilo como inhibidores de mek
UY33440A (es) ?compuestos pirimidinílicos para uso como inhibidores de atr?.
DOP2014000036A (es) Compuestos de piridazinona y su uso como inhibidores daao
CO7210068A1 (es) Nuevos derivados tienopirimidina, un proceso para su preparación y composiciones farmacéuticas que los contienen
CR20120443A (es) Derivados de (imidazopirimidina-7-il)-heteroarilamida y su uso como inhibidores de pde10a
UY35087A (es) Derivados de pirrolotriazinona como inhibidores de pi3k
BR112015026023A2 (pt) derivados de 2- aminopirido[4,3-d]pirimidin-5-ona e seu uso como inibidores de wee-1
UY35876A (es) Derivados de pirazolopirimidin-2-ilo como inhibidores de jak
UY32415A (es) NUEVOS DERIVADOS DE TETRAHIDROPIRAZOLO[3,4-c]ISOQUINOLIN-5-AMINA
ECSP15015088A (es) Derivados de pirrolotriazinona como inhibidores de pi3k
UY34430A (es) 18-metil-6,7-metilen-3-oxo-17-pregn-4-en-21,17bcarbolactona, preparados farmacéuticos que contienen los compuestos mencionados y su uso en la terapia de la endometriosis.